Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Total Non-Current Liabilities (2016 - 2025)

CytomX Therapeutics' Total Non-Current Liabilities history spans 10 years, with the latest figure at $48.2 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 58.75% year-over-year to $48.2 million; the TTM value through Dec 2025 reached $48.2 million, down 58.75%, while the annual FY2025 figure was $48.2 million, 58.75% down from the prior year.
  • Total Non-Current Liabilities reached $48.2 million in Q4 2025 per CTMX's latest filing, up from $46.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $346.6 million in Q4 2022 to a low of $46.6 million in Q3 2025.
  • Average Total Non-Current Liabilities over 4 years is $181.5 million, with a median of $186.5 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: dropped 6.56% in 2023, then tumbled 72.7% in 2025.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $346.6 million in 2022, then fell by 29.22% to $245.3 million in 2023, then tumbled by 52.36% to $116.9 million in 2024, then plummeted by 58.75% to $48.2 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Total Non-Current Liabilities are $48.2 million (Q4 2025), $46.6 million (Q3 2025), and $50.9 million (Q2 2025).